Compare Merck & Co., Inc. (MRK) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.89. The key difference: Merck & Co., Inc. pays a 2.29% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| MRK | USIG | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $52.69 |
52-Week Low | $77.60 | $49.89 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
USIG trades at $49.96, down 0.08% on the day, with technical indicators showing a bearish trend. Recent corporate actions include scheduled dividend payments in 2026. Institutional interest is evident from new stakes by Blue Edge Capital LLC and increased holdings by Bank of New York Mellon Corp, as reported by Defense World and Business Wire in July and August 2026.
The outlook remains cautious due to bearish technical signals and lack of recent fundamental data. Investment opportunities hinge on future financial disclosures and institutional support, while risks include market volatility and reliance on upcoming earnings for valuation clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
